Others

DSPE-PEG1000-MTP is a PEG compound which composed of DSPE and a muscle-targeting peptide (MTP). MTP is a muscle-targeting peptide with the property of targeting muscle tissue. DSPE-PEG1000-MTP can be used for drug delivery.

DSPE-PEG5000-MTP is a PEG compound which composed of DSPE and a muscle-targeting peptide (MTP). MTP is a muscle-targeting peptide with the property of targeting muscle tissue. DSPE-PEG5000-MTP can be used for drug delivery.

DSPE-PEG1000-VHPKQHRGGSKGC is a targeted modified phospholipid-polyethylene glycol conjugate covalently coupled to DSPE, PEG, and the vascular-targeting peptide VHPKQHRGGSKGC. DSPE-PEG1000-VHPKQHRGGSKGC can be used for research on tumor vascular imaging and vascular-targeted drug delivery.

DSPE-PEG3400-VHPKQHRGGSKGC is a targeted modified phospholipid-polyethylene glycol conjugate covalently coupled to DSPE, PEG, and the vascular-targeting peptide VHPKQHRGGSKGC. DSPE-PEG3400-VHPKQHRGGSKGC can be used for research on tumor vascular imaging and vascular-targeted drug delivery.

DSPE-PEG5000-VHPKQHRGGSKGC is a targeted modified phospholipid-polyethylene glycol conjugate covalently coupled to DSPE, PEG, and the vascular-targeting peptide VHPKQHRGGSKGC. DSPE-PEG5000-VHPKQHRGGSKGC can be used in research on tumor vascular imaging and vascular-targeted drug delivery.

Aristeromycin (ArDP) 5′-diphosphate is a carbocyclic nucleotide analog of adenosine diphosphate (ADP). Aristeromycin 5′-diphosphate acts as a key intermediate in the synthesis of bioactive compounds.

Glutathione sulfinanilide (GSOAN) is a derivative of Nitrosobenzene (HY-121641). Glutathione sulfinanilide can be generated by the reaction of Nitrosobenzene with GSH. Glutathione sulfinanilide is degradable in rat liver homogenate.

ED-594 is the glucuronide form of NB-506. ED-594 is one of the major metabolites of NB-506 in rat bile, mouse liver microsomes, rat liver microsomes and human liver microsomes.

DM243 is an EPAC1 activator and STAT3 modulator with an pIC₅₀ of 4.769 for EPAC1. DM243 increases GTP-bound Rap1 levels in EPAC1-expressing cells. DM243 reduces IL-6/IL-6Rα-evoked STAT3 phosphorylation in endothelial cells. DM243 suppresses TGF-β1-induced fibroblast-to-myofibroblast transition, reducing α-smooth muscle actin and Collagen I levels in lung fibroblasts. DM243 exhibits minimal cytotoxicity in normal human lung fibroblasts.

DM245 is an EPAC1 activator and STAT3 phosphorylation inhibitor with a target pIC₅₀ of 4.801. DM245 activates EPAC1 to increase Rap1-GTP levels, with no activation of EPAC2 or PKA. DM245 reduces IL-6/IL-6Rα-evoked STAT3 phosphorylation in endothelial cells. DM245 suppresses TGF-β1-induced fibroblast-to-myofibroblast transition, reducing αSMA and Collagen I levels. DM245 exhibits minimal cytotoxicity in normal human lung fibroblasts, with negligible loss of intact nuclei after 72 h exposure.

(S)-Thalidomide 4-fluoride is an E3 ligase linker conjugate that can be used for the synthesis of DeDPP4 (HY-182336).

PAK1-IN-3 is a PAK1 inhibitor with an IC₅₀ of 10 nM, an IC₅₀ of 20 nM against PAK2, and an IC₅₀ of 1079 nM against hERG potassium channels. PAK1-IN-3 forms a salt bridge with Asp106 in PAK1 via a properly positioned tertiary amine. PAK1-IN-3 inhibits PAK2 and hERG potassium channels.

BRD4 ligand 15 (compound 5) is a BRD4 ligand and alkyne-modified chalcone derivative, which serves as a building block for the synthesis of BRD4-targeting PROTAC TKP-5 (HY-182370).

ODZ10117 is a STAT3 and NLRP3 inhibitor with a human STAT3 SH2 domain IC₅₀ of 7.5 μM. ODZ10117 binds to the STAT3 SH2 domain, suppressing tyrosine phosphorylation, dimerization, nuclear translocation, and transcriptional activity. ODZ10117 binds to NLRP3, impairs NEK7 interaction, prevents inflammasome formation, and inhibits caspase-1 and IL-1β cleavage.ODZ10117 reduces MSU (HY-B2130A)-induced IL-1β release, lowers LPS (HY-D1056)-induced sepsis mortality, and exhibits anti-inflammatory effects. ODZ10117 induces apoptosis, suppresses breast cancer cell migration and invasion, reduces tumor growth and lung metastasis, and extends survival in breast cancer models. ODZ10117 can be used for the research of Monosodium urate (HY-B2130A)-induced peritonitis, LPS-induced sepsis, breast cancer, glioblastoma, and Alzheimer's disease.

GR-891 is an acyclic nucleoside 5-Fluorouracil (HY-90006) derivative. GR-891 exerts antiproliferative activity in human cancer cells and inhibits proliferation of human rhabdomyosarcoma cells. GR-891 induces terminal myogenic differentiation in human rhabdomyosarcoma cells, including modulation of desmin and vimentin expression. GR-891 is phosphorylated by kinases, incorporated into RNA, and releases acrolein. GR-891 can be used for the research of cancer and rhabdomyosarcoma.

MDL 100748 is an NMDA receptor glycine site antagonist. MDL 100748 modulates NMDA receptor function by acting at the strychnine-insensitive glycine site, which is required for NMDA receptor activation alongside glutamate. MDL 100748 decreases response rates in operant conditioning sessions in phencyclidin (PCP)-trained rats. MDL 100748 can be used for reserach on dementias and schizophrenia.

Cytochalasin Z2 is a 24-oxa-[14]cytochalasan. Cytochalasin Z2 is isolated from wheat cultures of Pyrenophora semeniperda. Cytochalasin Z2 shows no activity in root elongation assays of wheat and tomato seedlings.

GP515 is a potent and selective adenosine kinase inhibitor with a human IC₅₀ of 4 nM. GP515 exerts tissue protective effects, produces long-lasting hepatic microcirculation effects after hemorrhagic shock, and induces dose- and time-related VEGF mRNA and protein expression in normoxic rat myocardial myoblasts, with additive VEGF increases during mild hypoxia and no effect during severe hypoxia. GP515 suppresses IFNγ synthesis and CD69 expression in DSS-induced colitis. GP515 also shows a dose-dependent suppression of TNF-α production with an IC₅₀ of 80 μM and can be reversed in the presence of the cAMP antagonist (Rp)-cAMPS. Combinations of GP515 with either adenosine or rolipram led to an additive inhibition of TNF-α synthesis. GP515 can be used for the research of hemorrhagic shock.

ONO-8539 is an orally active prostanoid EP1 receptor antagonist with competitive, insurmountable binding and slow receptor dissociation for long-duration inhibition. ONO-8539 modulates afferent nerve function related to bladder activity, inhibits detrusor overactivity-related contractions, decreases nonvoiding contractions and voiding duration, and increases uroflow rate with ATP (HY-B2176)-induced detrusor overactivity. ONO-8539 attenuates acid-induced heartburn symptoms, extends time to first heartburn sensation, and prevents primary hypersensitivity after distal esophageal acidification. ONO-8539 can be used for the research of overactive bladder and gastroesophageal reflux disease.

U-19052 is a selective competitive peptidoleukotriene D/E receptor antagonist. U-19052 acts as a reversible antagonist that not affecting responses to non-leukotriene agonists. U-19052 does not exhibit agonist activity or induce contraction in guinea pig tracheal or ileal strips. U-19052 is a leukotriene antagonist developed by modifying leukotriene chemical structure. U-19052 can be used for the research of allergic asthma and hypersensitivity diseases.